AbbVie Gets Canada OK for Rinvoq in Adults With Rheumatoid Arthritis
January 07 2020 - 8:50AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. (ABBV) Tuesday said Health Canada approved Rinvoq
for the treatment of adults with moderately to severely active
rheumatoid arthritis who have had an inadequate response or
intolerance to methotrexate.
The North Chicago, Ill., biopharmaceutical company said Rinvoq
can be used as monotherapy or in combination with methotrexate or
other nonbiologic disease-modifying anti-rheumatic drugs.
AbbVie last year received approval from the U.S. Food and Drug
Administration and the European Commission for Rinvoq for adults
with rheumatoid arthritis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 07, 2020 08:35 ET (13:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
